Santarus Inc. (SNTS) Completes Patient Enrollment in CONTRIBUTE Study With UCERIS (budesonide) as Add-On Treatment to 5-ASA Drugs
7/18/2013 9:44:21 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
SAN DIEGO--(BUSINESS WIRE)--Santarus, Inc. (NASDAQ: SNTS) today announced the completion of enrollment in the CONTRIBUTE clinical study designed to evaluate the incremental benefit of adding UCERIS® (budesonide) extended release 9 mg tablets to oral aminosalicylate (5-ASA) therapy for the induction of clinical remission in adult patients with active, mild to moderate ulcerative colitis. UCERIS is currently approved in the U.S. for the induction of remission in patients with active, mild to moderate ulcerative colitis.
Help employers find you! Check out all the jobs and post your resume.
comments powered by